Takeda
Takeda bolsters data for dengue jab as regulatory reviews roll on
Phil Taylor
dengue fever, Dengue vaccine, Dengvaxia, Sanofi, Takeda, vaccine
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Closing the digital expectation gap in pharma
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Market Access, Jan Deman, market access, Takeda
0 Comment
Takeda, Daiichi-backed wearable study planned in Japan
Phil Taylor
Daiichi Sankyo, digital, digital health, Takeda, wearable
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Deep Dive: Market Access
mike.hammerton@pharmaphorum.com
Axon, Deep Dive, market access, Medscape, Novartis, Takeda
0 Comment
Takeda spinout Phathom claims its first FDA approvals
Phil Taylor
gastroenterology, Helicobacter pylori, Phathom Pharmaceuticals, regulatory approval, Takeda, vonoprazan, Voquezna
0 Comment
NHS grants fast-track access to Takeda’s lung cancer drug Exkivity
Phil Taylor
access, EGFR, Exkivity, NHS, Non-small cell lung cancer, Oncology, Project Orbis, Takeda
0 Comment
Takeda grows in gene therapies again with $2bn Code Bio deal
Phil Taylor
Code Bio, gene therapy, partnering, Takeda
0 Comment
FDA knocks back Takeda’s blockbuster hope TAK-721
Phil Taylor
eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda
0 Comment